Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTU-multHIV B vaccine + LIPO-5 vaccine
- Development stage
- Unknown
- Lead developer
- FIT Biotech
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular, Intradermal
01
Overview
GTU-multHIV B vaccine + LIPO-5 vaccine is a combination of two investigational therapeutic HIV vaccines designed to stimulate immune responses in people living with HIV. The GTU-multHIV B component is a DNA-based therapeutic vaccine encoding multiple HIV antigens (including Rev, Nef, Tat, p17/p24, and Pol/Env epitopes) from clade B HIV. It aims to induce strong cell-mediated immunity by delivering plasmid DNA encoding these antigens[1][6][9]. The LIPO-5 component is a peptide-based therapeutic HIV vaccine consisting of five synthetic lipopeptides derived from conserved regions of the Gag, Pol, and Nef proteins of HIV; it is formulated with lipid moieties to enhance immunogenicity. This combination has been studied as part of prime-boost strategies for enhancing cellular immune responses in people on suppressive antiretroviral therapy (ART). Both vaccines are intended for use as immunotherapeutic agents rather than preventive vaccines.
- Other names
- GTU-MultiHIV B DNA vaccine + LIPO-5 peptide vaccine
02
Targets
HIV-1 antigens
Beyond the preview
Go deeper on GTU-multHIV B vaccine + LIPO-5 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTU-multHIV B vaccine + LIPO-5 vaccine.